Ian W. Flinn, MD, PhD

Ian Flinn, MD, PhD, director of lymphoma research at the Sarah Cannon Cancer Institute, highlights findings in Hodgkin lymphoma presented at the 2021 meeting of the American Society of Hematology. 

The first study that Dr Flinn discusses combined pembrolizumab with AVD in patients with untreated Hodgkin lymphoma. This regimen was found to be both safe and effective, with high overall response, progression-free survival, and overall survival rates. 

Another study he examines combined pembrolizumab with ICE chemotherapy prior to autologous hematologic stem cell transplant. The primary endpoint of complete metabolic response was met and the regimen demonstrated a tolerable safety profile. 

Next, Dr Flinn looks at a study comparing seven novel and conventional salvage therapies. Most notably, brentuximab vedotin plus nivolumab demonstrated a higher complete remission rate and better post-autologous stem cell transplant progression-free survival compared with chemotherapy. 

Dr Flinn concludes with a phase 2 study that evaluated first-line nivolumab in older frail patients. The primary objective of complete metabolic response rate was not reached, with safety findings comparable to those of published data in this population. 

--

Ian W. Flinn, MD, PhD, Director, Lymphoma Research; Principal Investigator, Sarah Cannon Cancer Institute, Nashville, Tennessee 

Ian W. Flinn, MD, PhD, has disclosed the following relevant financial relationships: 

Serve(d) as a consultant: AbbVie; AstraZeneca; BeiGene; Century Therapeutics; Genentech; Gilead Sciences; Great Point Partners; Hutchison MediPharma; Iksuda Therapeutics; Janssen; Juno Therapeutics; Kite Pharma; MorphoSys; Novartis; Nurix Therapeutics; Pharmacyclics; Roche; Seattle Genetics; Takeda; TG Therapeutics; Unum Therapeutics; Verastem; Vincerx Pharma; Yingli Pharmaceuticals 

Institute received research grant from: AbbVie; Acerta Pharma; Agios; ArQule; AstraZeneca; BeiGene; Calithera Biosciences; Celgene; Constellation Pharmaceuticals; Curis; Forma Therapeutics; Forty Seven; Genentech; Gilead Sciences; IGM Biosciences; Incyte; Infinity Pharmaceuticals; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite Pharma; Loxo; Merck; MorphoSys; Novartis; Pfizer; Pharmacyclics; Portola Pharmaceuticals; Rhizen Pharmaceuticals; Roche; Seattle Genetics; Takeda; Teva Pharmaceuticals; TG Therapeutics; Trillium Therapeutics; Triphase Research & Development; Unum Therapeutics; Verastem 

Ian Flinn, MD, PhD, director of lymphoma research at the Sarah Cannon Cancer Institute, highlights findings in Hodgkin lymphoma presented at the 2021 meeting of the American Society of Hematology. 

The first study that Dr Flinn discusses combined pembrolizumab with AVD in patients with untreated Hodgkin lymphoma. This regimen was found to be both safe and effective, with high overall response, progression-free survival, and overall survival rates. 

Another study he examines combined pembrolizumab with ICE chemotherapy prior to autologous hematologic stem cell transplant. The primary endpoint of complete metabolic response was met and the regimen demonstrated a tolerable safety profile. 

Next, Dr Flinn looks at a study comparing seven novel and conventional salvage therapies. Most notably, brentuximab vedotin plus nivolumab demonstrated a higher complete remission rate and better post-autologous stem cell transplant progression-free survival compared with chemotherapy. 

Dr Flinn concludes with a phase 2 study that evaluated first-line nivolumab in older frail patients. The primary objective of complete metabolic response rate was not reached, with safety findings comparable to those of published data in this population. 

--

Ian W. Flinn, MD, PhD, Director, Lymphoma Research; Principal Investigator, Sarah Cannon Cancer Institute, Nashville, Tennessee 

Ian W. Flinn, MD, PhD, has disclosed the following relevant financial relationships: 

Serve(d) as a consultant: AbbVie; AstraZeneca; BeiGene; Century Therapeutics; Genentech; Gilead Sciences; Great Point Partners; Hutchison MediPharma; Iksuda Therapeutics; Janssen; Juno Therapeutics; Kite Pharma; MorphoSys; Novartis; Nurix Therapeutics; Pharmacyclics; Roche; Seattle Genetics; Takeda; TG Therapeutics; Unum Therapeutics; Verastem; Vincerx Pharma; Yingli Pharmaceuticals 

Institute received research grant from: AbbVie; Acerta Pharma; Agios; ArQule; AstraZeneca; BeiGene; Calithera Biosciences; Celgene; Constellation Pharmaceuticals; Curis; Forma Therapeutics; Forty Seven; Genentech; Gilead Sciences; IGM Biosciences; Incyte; Infinity Pharmaceuticals; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite Pharma; Loxo; Merck; MorphoSys; Novartis; Pfizer; Pharmacyclics; Portola Pharmaceuticals; Rhizen Pharmaceuticals; Roche; Seattle Genetics; Takeda; Teva Pharmaceuticals; TG Therapeutics; Trillium Therapeutics; Triphase Research & Development; Unum Therapeutics; Verastem 

Ian Flinn, MD, PhD, director of lymphoma research at the Sarah Cannon Cancer Institute, highlights findings in Hodgkin lymphoma presented at the 2021 meeting of the American Society of Hematology. 

The first study that Dr Flinn discusses combined pembrolizumab with AVD in patients with untreated Hodgkin lymphoma. This regimen was found to be both safe and effective, with high overall response, progression-free survival, and overall survival rates. 

Another study he examines combined pembrolizumab with ICE chemotherapy prior to autologous hematologic stem cell transplant. The primary endpoint of complete metabolic response was met and the regimen demonstrated a tolerable safety profile. 

Next, Dr Flinn looks at a study comparing seven novel and conventional salvage therapies. Most notably, brentuximab vedotin plus nivolumab demonstrated a higher complete remission rate and better post-autologous stem cell transplant progression-free survival compared with chemotherapy. 

Dr Flinn concludes with a phase 2 study that evaluated first-line nivolumab in older frail patients. The primary objective of complete metabolic response rate was not reached, with safety findings comparable to those of published data in this population. 

--

Ian W. Flinn, MD, PhD, Director, Lymphoma Research; Principal Investigator, Sarah Cannon Cancer Institute, Nashville, Tennessee 

Ian W. Flinn, MD, PhD, has disclosed the following relevant financial relationships: 

Serve(d) as a consultant: AbbVie; AstraZeneca; BeiGene; Century Therapeutics; Genentech; Gilead Sciences; Great Point Partners; Hutchison MediPharma; Iksuda Therapeutics; Janssen; Juno Therapeutics; Kite Pharma; MorphoSys; Novartis; Nurix Therapeutics; Pharmacyclics; Roche; Seattle Genetics; Takeda; TG Therapeutics; Unum Therapeutics; Verastem; Vincerx Pharma; Yingli Pharmaceuticals 

Institute received research grant from: AbbVie; Acerta Pharma; Agios; ArQule; AstraZeneca; BeiGene; Calithera Biosciences; Celgene; Constellation Pharmaceuticals; Curis; Forma Therapeutics; Forty Seven; Genentech; Gilead Sciences; IGM Biosciences; Incyte; Infinity Pharmaceuticals; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite Pharma; Loxo; Merck; MorphoSys; Novartis; Pfizer; Pharmacyclics; Portola Pharmaceuticals; Rhizen Pharmaceuticals; Roche; Seattle Genetics; Takeda; Teva Pharmaceuticals; TG Therapeutics; Trillium Therapeutics; Triphase Research & Development; Unum Therapeutics; Verastem